China NMPA accepts BeiGene’s sBLA for tislelizumab in combo with chemotherapy to treat recurrent nasopharyngeal cancer

Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Original source:

Related Posts